NCT06467539 · Phase 2 · RECRUITING
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
This trial compares two combinations in people with early Alzheimer's or mild cognitive impairment: DAOIB (a compound that boosts NMDA receptor activity in the brain) plus an antioxidant, versus DAOIB plus a placebo. Researchers want to see if adding the antioxidant helps thinking more. It is a Phase 2 trial, testing whether it works and is safe, not yet proven or approved.
You may qualify if
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
You're excluded if
- Hachinski Ischemic Score > 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-19